BCL2 and leukemia: We and others have previously shown BCL2 to be active in t(9;22) ALL.6, 46 In this context we identify drug combination imatinib/ABT-199 to show synergism in BCR/ABL leukaemia (CI=0.88) (Figures 8b, e and h).